

**NEW JERSEY DRUG UTILIZATION REVIEW BOARD  
VIRTUAL PLATFORM**

July 15, 2020

<http://www.state.nj.us/humanservices/dmahs/boards/durb/>

**AGENDA**

- I. Call to order in accordance with New Jersey Open Public Meeting Act
- II. Roll Call
- III. Review of meeting transcript for January 22, 2020 meeting (URL)
- IV. Review of draft meeting summary for January 22, 2020 meeting
- V. Secretary's report
- VI. Old Business
  - A. United Healthcare Clinical Criteria Not Met (CCNM) report
  - B. Amerigroup CCNM report
  - C. Resolution rate for CCNM and non-formulary drugs PA requests – Sam Currie/Ed Vaccaro
  - D. Addendum to Dupixent® (dupilumab) protocol
  - E. Addendum to Emflaza® (deflazacort) protocol
  - F. Addendum to PCSK9 Inhibitors protocol
- VII. New Business
  - A. Proposed protocol for Varubi® (rolapitant)
  - B. Proposed protocol for Vyondys 53® (golodirsen)
  - C. Proposed protocol for Cryopyrin-associated periodic syndromes (CAPS) products
  - D. Proposed protocol for Spravato® (esketamine)
- VIII. Proposed Educational Newsletter on MAT drugs
- IX. Top (25) Drugs utilization review – 2017 thru 2019
- X. A. Informational Highlights/Reports
  1. DXC Technology/NJ HMO 4<sup>th</sup> Quarter 2019 Prior Authorization Report
  2. Summary of DURB Action Items
  3. (a) DHS, DHSS and MCO Programs Top Drugs Report (by amount paid and by category) [URL]  
(b) Physician-administered/Antiviral drugs by amount paid [URL]
- B. Medication information:
  1. Protocol for the use of Investigational Drugs for the Treatment of COVID-19
  2. Reversal of Protocol or Investigational Drugs for the Treatment of COVID-19
  3. Coronavirus (COVID-19) Treatment Hub
  4. Metformin ER recall